Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9552W HIGH $10.21
Volume
17.11 K
Value Traded
119.91 K
Short % Float
0.29%
-8.51%Week
-53.12%1 Month
+146.72%3 Month
+79.17%6 Month
-99.7%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
45.72 M
EPS (TTM)
0.74
P/E Ratio
4.08
Ent. Value
12.29 M
Total Shares
15.19 M
Float Shares
7.39 M
Insiders
51.67%
Institutions
0.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MBAI Catalyst Timeline
Dated clinical, regulatory and corporate events for Check-Cap Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Check-Cap Ltd.
14Total events
1Upcoming
7Tier-1 (high impact)
2024 to 2026Coverage
Event history 12
▲Quarterly UpdateCorporate
Fortune 500 operator expands deployment from pilot to multi-property
▲Quarterly UpdateCorporate
Regained compliance with Nasdaq minimum shareholders' equity requirement
◆Quarterly UpdateCorporate
Annual General Meeting of Shareholders to vote on Merger Proposal, Reverse Split Proposal, and Director Election
Past FDA Catalysts and PDUFA Decisions
How MBAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Check-Cap Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MBAI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MBAI for Q2 2026. | ||||
MBAI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBAI ranks across every disease it competes in
Competitive Position is a premium feature
See how MBAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBAI News
MBAI▲ +6.3%on this news· ran to +26% by day 1
MBody AI Corp, Inc. Index to Financial Statements Table of Contents Page Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 7158) 2 Financial Statements Balance Sheets 4 Statements of Operations 5 St
MBody AI Corp has released its financial statements audited for the year ending December 31, 2025. The audit indicates that the financial position and results of operations are presented fairly, adhering to GAAP principles. Notably, the company reported significant revenues from customer subscription contracts, leading to a positive net income for the period. The total assets have substantially increased, reflecting growth in the company’s financial standing.
Read more →MBAIMBody AI Corp. Expands Fortune 500 Deployment, Advancing National Robotics Rollout
MBody AI Corp. has announced the expansion of its deployment with a Fortune 500 gaming and hospitality operator, transitioning from a pilot program to a multi-property rollout. This expansion leverages successful live operations that demonstrated consistent performance. Currently, the deployment covers less than 10% of the operator's national footprint, indicating significant growth potential in the relationship. The agreement involves autonomous floor care with plans to broaden services across various categories, contributing to a recurring revenue model.
Read more →MBAIMBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close
MBody AI has submitted its Nasdaq listing application, marking a key regulatory step towards the merger with Check-Cap Ltd. This move is anticipated to facilitate the combined company's successful listing on Nasdaq by the first half of 2026. Recent milestones include regaining compliance with Nasdaq requirements and filing important financial documentation. Both company leaders express optimism about the future, emphasizing the potential for significant opportunities in the embodied AI market.
Read more →MBAI▼ -11.1%on this news· ran to -23% by day 1
MBody AI Corp, Inc. Index to Financial Statements Table of Contents Page Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 7158) 2 Financial Statements Balance Sheets 3 Statements of Operations 4 St
MBody AI Corp has released its financial statements for the period ending June 30, 2025. The audit report indicates the statements present an accurate depiction of the company’s finances, despite a net loss reported during this period. The transition toward a software-as-a-service model could enhance future revenue streams, while current operating expenses have risen significantly, raising concerns about financial sustainability.
Read more →MBAI▲ +112.1%on this news
Check-Cap Clears Key Nasdaq Requirement, Advancing MBody AI Merger Milestone achieved as shareholder-approved merger with MBody AI
Check-Cap Ltd. has confirmed its compliance with Nasdaq's minimum shareholders' equity requirements, a crucial step towards finalizing the merger with MBody AI. This merger, which has already garnered 98% shareholder approval, aims to position Check-Cap as a leader in the embodied artificial intelligence sector. The transition to being a publicly traded entity is anticipated to enhance the visibility and scalability of MBody AI's technology across various industries. With this regulatory clearance, Check-Cap is now focused on the execution of final transaction steps.
Read more →MBAIConsolidated Unaudited Financial Statements of Check-Cap Ltd. A s of and for the six months ended
Check-Cap Ltd. released its unaudited financial statements for the six months ending June 30, 2025. The company reported significant improvements in total current assets and a turnaround in net income, reaching $5.213 million. However, persistent accumulated deficits and the discontinuation of research and development activities raise concerns about the company's ongoing viability, as it evaluates strategic alternatives and a planned merger with MBody AI Corp. The management's assessment of going concern remains uncertain owing to limited revenue generation and high liabilities.
Read more →MBAI▼ -11.8%on this news
MBody AI To Begin Trading Under New Nasdaq Ticker Symbol "MBAI"
MBody AI Corp. announced its transition to a new Nasdaq ticker symbol "MBAI", effective December 2, 2025, following its merger with Check-Cap Ltd. This change marks the company's evolution into a publicly traded leader in embodied artificial intelligence. The firm seeks to drive enterprise automation through a hardware-agnostic AI platform capable of integrating diverse robotic and sensor systems. Both leadership executives expressed confidence in the company's position within the rapidly evolving AI landscape.
Read more →MBAIMBody AI ($CHEK) Secures
MBody AI Corp. has received overwhelming support from Check-Cap shareholders, with over 98% voting in favor of their merger, which is expected to close shortly. This merger will establish MBody AI as a key player in the embodied AI sector on Nasdaq. The company provides a hardware-agnostic platform aimed at automating operations across multiple industries, appealing particularly to enterprises seeking efficiency and scalability in their processes.
Read more →MBAICheck-Cap Ltd. Check-Cap Building 29 Abba Hushi Avenue P.O. Box 1271 Isfiya, 3009000 Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting
Check-Cap Ltd. has announced its upcoming Annual General Meeting scheduled for October 17, 2025. At this meeting, shareholders will vote on a proposal for the merger with MBody AI, which will also result in a name change for Check-Cap. Additionally, management representatives will review the company's financial statements for the fiscal year ending December 31, 2024. The merger is anticipated to create synergies and expand operational capabilities in various sectors.
Read more →MBAICHECK CAP LTD CONSOLIDATED UNAUDITED BALANCE SHEETS (U.S. dollars in thousands, except share and per share data) June 30
Check Cap Ltd reported its unaudited consolidated balance sheets, revealing a drop in total assets to $18,090 thousand as of June 30, 2024, down from $25,017 thousand at year-end 2023. The company posted a net loss of $6,312 thousand for the first half of 2024, showcasing a steep increase in its accumulated deficit. Notably, the firm has halted its ongoing calibration studies and decided against initiating the powered portion of its pivotal study due to prior efficacy results not meeting expectations. This decision accompanies significant workforce reductions aimed at preserving cash flow amidst ongoing operational challenges.
Read more →MBAICheck-Cap Ltd. Check-Cap Building 29 Abba Hushi Avenue P.O. Box 1271 Isfiya, 3009000 Israel AMENDED NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: On
Check-Cap Ltd. has announced an amended notice for an Extraordinary General Meeting of Shareholders scheduled for April 25, 2024, at The Ritz Carlton in Toronto, Canada. The amendment reflects a change in the meeting's location, but no alterations have been made to the proposed resolutions. Shareholders of record will be entitled to vote on various proposals, including compensation and board member appointments. The company ensures that shareholders have clear instructions on how to participate and vote during the meeting.
Read more →MBAIPROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS This Proxy Statement is furnished to our holders of ordinary shares, par value NIS 48.00 (the "Ordinary Shares"), in connection with Extraordinary General Mee
Check-Cap Ltd. is holding an Extraordinary General Meeting for shareholders on April 25, 2024. Shareholders with Ordinary Shares as of March 25, 2024, are eligible to vote on various proposals. The Board of Directors recommends that shareholders vote in favor of proposals 1 to 7. Additionally, guidelines for proxy voting and meeting procedures are outlined in the statement. A quorum of at least 25% of voting rights is required for the meeting to proceed.
Read more →MBAIBUSINESS COMBINATION AGREEMENT BETWEEN NOBUL AI CORP. - AND - CHECK-CAP LTD. DATED AS OF MARCH 25, 2024 TABLE OF CONTENTS Article 1 DEFINITIONS AND INTERPRETATION 1 1.1 Certain Definitions. 1 1.2 Further Definitions. 14
Nobul AI Corp. and Check-Cap Ltd. have entered into a business combination agreement as of March 25, 2024. The agreement outlines the merger process where a wholly owned subsidiary of Nobul will merge with Check-Cap. The Check-Cap Board has reviewed the merger and deemed it fair and advisable for its shareholders, backed by an independent financial advisor's approval. This agreement highlights the intention of both parties to enhance their business operations and shareholder value through this strategic merger.
Read more →MBAIGraham Schmidt
Graham Schmidt has announced his resignation from the Board of Directors of Check-Cap Ltd, effective January 22, 2024. He expressed gratitude for the opportunity to serve and extended his best wishes for the company's future. This decision comes after careful consideration, and Schmidt looks forward to observing Check-Cap's continued progress.
Read more →About Check-Cap Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next MBAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime